MIRM Stock Summary and Trading Ideas (Mirum Pharmaceuticals | NASDAQ:MIRM)

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Mirum Pharmaceuticals trades on the NASDAQ stock market under the symbol MIRM.

As of June 5, 2026, MIRM stock price climbed to $93.48 with 545,589 million shares trading.

MIRM has a beta of 1.12, meaning it tends to be more sensitive to market movements. MIRM has a correlation of 0.11 to the broad based SPY ETF.

MIRM has a market cap of $5.70 billion. This is considered a Mid Cap stock.

Last quarter Mirum Pharmaceuticals reported $160 million in Revenue and -$.50 earnings per share. This beat revenue expectation by $12 million and missed earnings estimates by -$.14.

In the last 3 years, MIRM traded as high as $114.99 and as low as $23.14.

The top ETF exchange traded funds that MIRM belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.

MIRM has outperformed the market in the last year with a return of +109.4%, while the SPY ETF gained +25.6%. However, in the most recent history, MIRM shares have underperformed the stock market with its stock returning +6.4% in the last 3 month period and -5.2% for the last 2 week period, while SPY has returned +8.5% and -1.1%, respectively.

MIRM support price is $89.14 and resistance is $95.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIRM shares will trade within this expected range on the day.